Insulet Corporation reported fourth‑quarter 2025 revenue of $783.8 million, up 31% from $597.5 million in Q4 2024, and net income of $101.6 million. GAAP diluted earnings per share were $1.44, slightly below the consensus estimate of $1.48, while adjusted EPS of $1.55 beat the consensus estimate of $1.46 by $0.09, reflecting disciplined cost control and a favorable product mix.
Gross margin rose to 72.5% from 72.1% in the prior year, an increase of 40 basis points, driven by higher average selling prices and manufacturing scale gains, particularly in the U.S., China, and Malaysia facilities. The margin lift was supported by the continued adoption of the Omnipod 5 tubeless insulin pump, which has captured market share in both type 1 and type 2 diabetes segments.
For the first quarter of 2026, Insulet expects U.S. revenue growth of 24%–26% and international growth of 37%–39%, translating to total Omnipod product revenue growth of 28%–30%. Full‑year 2026 revenue guidance is a constant‑currency growth range of 20%–22%, and adjusted EPS guidance is projected to grow more than 25% from the prior year, indicating confidence in sustained demand and margin expansion.
The board increased the share‑repurchase authorization by $350 million, bringing the total to $475 million, and plans to deploy approximately $300 million in buybacks in Q1 2026, underscoring management’s confidence in the company’s financial strength.
CEO Jim Hollingshead said the company “concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives.” CFO Flavia Pease highlighted that the company “closed with an impressive fourth quarter, delivering over $780 million in total revenue, an increase of 31.2% at reported rates and 29% at constant currency rates.”
Investors responded positively to the earnings beat, but the nuanced 2026 outlook tempered enthusiasm.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.